Abstract Topics
Abstract Submission Is Open!
The submission deadline is September 17, 2024.
List of accepted Abstract Topics:
- Real-World Experience, Novel Clinical Approaches, and Combination Therapies: Potential synergy between engineered lymphocytes & other treatment modalities will be demonstrated.
- Superpowered Lymphocytes: Learn more about the engineering of lymphocytes for the co-expression of varied immune effectors in addition to the transgenic receptor.
- Non-Viral CAR/TCR Gene Targeting: Recent advancements in promoting integration into lymphocyte genomes by means of nucleases or transposons.
- CAR/TCR mRNA Therapies: Exploring the therapeutic effects of transient CAR/TCR expression using mRNA delivery.
- Universal Donor Cells & Advanced TCR Engineering: A deeper look at allogeneic therapies, including those applying genome editing technologies.
- Updated Clinical Data: First, look at post marketing real world data on the approved T cell therapies.
- Beyond Alpha-Beta T Cells: Discuss the engineering of alternative leukocytes, including Gamma-Delta T cells, iNKT cells, NK cells, B cells, and macrophages.
- Targeting Non-Malignant Diseases: Targeting non-malignant diseases, including infectious diseases, auto-immune diseases, cardiovascular diseases, genetic disorders, and more.
- In Vivo and Bedside T Cell Engineering: Advancement in the scalable engineering of lymphocytes in vivo, reducing costs, timelines, and preconditioning requirements.
SUBMIT HERE
Don't miss your chance to get your work published!
All accepted abstracts from ICLE 2025 will be published in
Human Gene Therapy
(Impact Factor 4.2*)
*2022 Journal Citation Reports™ (Clarivate, 2023)
CiteScore™: 7
LEARN MORE